UroGen Pharma Ltd.: net current accounts receivable
Net current accounts receivable for UroGen Pharma Ltd. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All UroGen Pharma Ltd. financial histories
What this measure means
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
Exact concept: us-gaap:AccountsReceivableNetCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 33,082,000 | USD | 2026-03-02 | 10-K · 0001437749-26-006234 |
| At date | 2024-12-31 | 20,302,000 | USD | 2026-03-02 | 10-K · 0001437749-26-006234 |
| At date | 2023-12-31 | 15,443,000 | USD | 2025-03-10 | 10-K · 0001437749-25-006842 |
| At date | 2022-12-31 | 12,704,000 | USD | 2024-03-14 | 10-K · 0001437749-24-007753 |
| At date | 2021-12-31 | 11,717,000 | USD | 2023-03-24 | 10-K · 0001437749-23-007710 |
| At date | 2020-12-31 | 7,047,000 | USD | 2022-03-21 | 10-K · 0001437749-22-006778 |
| At date | 2016-12-31 | 83,000 | USD | 2018-03-15 | 20-F · 0001564590-18-005876 |
Related financial histories
- UroGen Pharma Ltd.: total assets
- UroGen Pharma Ltd.: total liabilities
- UroGen Pharma Ltd.: stockholders equity
- UroGen Pharma Ltd.: cash and cash equivalents
- UroGen Pharma Ltd.: net income or loss
- UroGen Pharma Ltd.: operating cash flow
- UroGen Pharma Ltd.: capital expenditure payments
- UroGen Pharma Ltd.: revenue
- UroGen Pharma Ltd.: contract revenue excluding tax
- UroGen Pharma Ltd.: financing cash flow
- UroGen Pharma Ltd.: investing cash flow
- UroGen Pharma Ltd.: retained earnings or deficit
- UroGen Pharma Ltd.: basic weighted-average shares
- UroGen Pharma Ltd.: basic earnings per share
- UroGen Pharma Ltd.: income tax expense or benefit
- UroGen Pharma Ltd.: net property, plant and equipment
- UroGen Pharma Ltd.: share-based compensation expense
- UroGen Pharma Ltd.: operating income or loss
- UroGen Pharma Ltd.: current assets
- UroGen Pharma Ltd.: current liabilities
- UroGen Pharma Ltd.: current accounts payable
- UroGen Pharma Ltd.: operating expenses
- UroGen Pharma Ltd.: net inventory
- UroGen Pharma Ltd.: gross profit
- UroGen Pharma Ltd.: cost of revenue
- UroGen Pharma Ltd.: selling, general and administrative expense
- UroGen Pharma Ltd.: research and development expense
Inspect the source
- Entity
- UroGen Pharma Ltd. / CIK 0001668243
- Captured
- 2026-09-21T17:22:34.317Z
- SEC response SHA-256
c0f9fceebc685f0377739af490e9f9cff0a1b4a6e8cf3110d6b22e5d217158cf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001668243.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))